ITK and hepatocellular carcinoma: Besides its intended BTK effects, ibrutinib also deactivates several off-targets, including epidermal growth factor receptor (EGFR), ErbB2, interleukin-2-inducible T cell kinase (ITK), and tyrosine kinase expressed in hepatocellular carcinoma (TEC) [60].